loading...| Preferred Name | Cabozantinib S-malate | |
| Synonyms |
CABOZANTINIB S-MALATE Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1) Cabozantinib S-malate BMS-907351 Cabometyx Cometriq XL-184 XL184 |
|
| Definitions |
The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C97938 |
|
| Accepted_Therapeutic_Use_For |
advanced renal cell carcinoma (RCC); hepatocellular carcinoma (HCC) |
|
| CAS_Registry |
1140909-48-3 |
|
| Chemical_Formula |
C28H24FN3O5.C4H6O5 |
|
| code |
C97938 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC |
|
| DEFINITION |
The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. |
|
| Display_Name |
Cabozantinib S-malate |
|
| FDA_UNII_Code |
DR7ST46X58 |
|
| FULL_SYN |
CABOZANTINIB S-MALATE Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1) Cabozantinib S-malate BMS-907351 Cabometyx Cometriq XL-184 XL184 |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C18186 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28496 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17328 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C18488 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17475 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C26203 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C26202 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C33983 |
|
| Is_Value_For_GDC_Property | ||
| label |
Cabozantinib S-malate |
|
| Maps_To |
Cabozantinib S-malate |
|
| NCI_Drug_Dictionary_ID |
461103 |
|
| PDQ_Closed_Trial_Search_ID |
461103 |
|
| PDQ_Open_Trial_Search_ID |
461103 |
|
| Preferred_Name |
Cabozantinib S-malate |
|
| prefixIRI |
Thesaurus:C97938 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C3468008 |
|
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C93259 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C200418 |